Skip to main content
Premium Trial:

Request an Annual Quote

Quinvita Gets $1M Grant for Jatropha Studies

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The agricultural biotech company Quinvita has landed a €715,000 ($1 million) grant from the Flemish government to fund efforts to study the genome of Jatropha curcas, a durable tree used to make oil for biofuels.

The Ghent, Belgium-based company will use the three-year grant from the agency for Innovation by Science and Technology in Flanders (IWT) to support a partnership with researchers at the Catholic University of Leuven (KU Leuven) to start an R&D program focused on Jatropha agronomy and genetics.

Jatropha is known for its abilities to grow well in various environments, including tropical and sub-tropical regions, in wastelands and on a range of terrains, including gravelly, sandy, and saline soils.

"The award of the IWT grant is a vote of confidence in the quality of work ongoing on Jatropha curcas in Flanders," KU Leuven Professor of Forest Ecology and Management Bart Muys said in a statement.

Quinvita CEO Henk Joos said the funding will strengthen the company's collaboration with Muys' team at KU Leuven, "which has proven through their recent scientific publications to be one of the leading research groups in the world on Jatropha curcas."

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.